[2] 李连第，张思维，鲁凤珠，等. 中国恶性肿瘤死亡谱及分类构成特征研究[J]. 中华肿瘤杂志，1997，19（5）：323.

[3] 刘俊主编.上海卫生年鉴1997[M].上海科学技术出版社，1997.628.

[4] Mulshine JL. Biology: The early detection of lung cancer[J]. Lung Cancer , 1997, 18(2su l):37.

[5] Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on

individuals patients from 52 randomized clinical trials[J]. B.M.J., 1995: 899-909.

[6] Rosell, R., Font, A., Pifarr A., et al. Chest, 1996, 109: S102-S106.

[7] Martini, N., Kris, M.G., Flehinger, B.J., et al. A . Thorac. Surg., 1993, 55: 1365-1374.

[8] Sugarbaker, D.J., Herndon, J., Kohman, L.J., et al. Thorac. Cardiovasc. Surg., 1995, 109: 473-485.

[9] Pa , H.I., Pogre iak, H.W., Stei erg, S.M., et al.A . Thorac. Surg., 1992, 53: 992-998.

[10] Rosell, R., Gez-Codina, J., Cam , C., et al. Med., 1994, 330: 153-158.

[11] Rosell, R., Gez-Codina, J., Cam , C., et al. Lung Cancer, 1999, 26: 7-14.

[12] Roth, J.A., Fo ella, F., Komaki, R., et al. Cancer I t., 1994, 86: 673-680.

[13] Roth, J.A., Atki on, E.N., Fo ella, F., et al. Lung Cancer, 1998, 21:1-6.

[14] Rosell, R., Lez-Cabrerizo, M.P., Astudillo, J. Curr. Opin. Oncol., 1997, 9: 149-155.

[15] Shepherd, F.A., Joh ton, M.R., Payne, D., et al.Cancer, 1998, 78: 683-685.

[16] Choi, N.C., Carey, R.W., Daly, W., et al.Clin. Oncol., 1997, 15: 712-722.

[17] Eberhardt, W., Wilke, H., Stamatis, G., et al.Clin. Oncol., 1998, 16: 622-634.

[18] Thomas, M., Rube, C., Semik, M., et al. Clin. Oncol., 1999, 17: 1185-1193.

[19] Felip, E., Rosell, R., Alberola, V., et al. Clinical Lung Cancer, 2000, 4: 287-293.

[20] Pieterman, R.M., van Putten, J.W.G., Meuzelaar, J.J., et al. Med., 2000, 343: 254-261.

[21] Rosell, R., Felip, E. Semin. Surg. Oncol., 2000, 18: 143-151.

[22] Pisters, K.M., Gi erg, R.J., Giraux, D.J., et al. D.H. J. Thorac[J]. Cardiovasc. Surg., 2000, 1199, 429-439.

[23] 廖美琳，林震琼，周允中，等. 前瞻性非小细胞肺癌分子生物学检测和期别、类型及生存率间的相关性研究[J].肿瘤, 1996，16（2）su l:148.

[24] Feld R, Rubi tein LV, Weise urger TH, et al. Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future

studies [J]. J Clin Oncol 1984, 2(8): 1352.

[25] Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and P53 mutatio are an independent unfavourable prognostic indicator in patients

with non-small cell lung cancer [J]. Br J Cancer, 1997, 75( 8):1125.

[26] Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovasculature to metastasis of non-small cell lung cancer[J]. Lancer, 1992,

340: 145.

[27]廖美琳，赵家美，张新敏，等. 术后化疗周期对化疗结合手术治疗局限期小细胞肺癌的预后影响[J].中华结核和呼吸杂志,1990,14

（2）：104.

[28] Holmes EC, Gail M. Surgical adjuvant therapy for stage II and stage III Adenocarcinoma and large cell undifferentiated carcinoma [J].J

Clin Oncol, 1986, 4(3): 710